Multi-centre trial of aprotinin highlights increased safety with higher dose.
D007611:Aprotinin / Q000008:administration & dosage* / Q000627:therapeutic use; D006490:Hemostatics / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D015337:Multicenter Studies as Topic; D016032:Randomized Controlled Trials as Topic; D012449:Safety
D006490:Hemostatics; D007611:Aprotinin